AR083575A1 - Aminopirazoles para inhibir la proteinquinasa chk1 - Google Patents
Aminopirazoles para inhibir la proteinquinasa chk1Info
- Publication number
- AR083575A1 AR083575A1 ARP110103973A ARP110103973A AR083575A1 AR 083575 A1 AR083575 A1 AR 083575A1 AR P110103973 A ARP110103973 A AR P110103973A AR P110103973 A ARP110103973 A AR P110103973A AR 083575 A1 AR083575 A1 AR 083575A1
- Authority
- AR
- Argentina
- Prior art keywords
- proteinquinase
- aminopirazols
- chk1
- inhibit
- hemioxalate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Sales de ácido metansulfónico, acido acético, hemioxalato, hemisuccinato. Útil en el tratamiento de cáncer.Reivindicación 1: Un compuesto caracterizado porque es (R)-[5-(2-metoxi-6-metil-piridin-3-il)-2H-pirazol-3-il]-[6-(piperidin-3-iloxi)-pirazin-2-il]-amina de fórmula (1), o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41113710P | 2010-11-08 | 2010-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083575A1 true AR083575A1 (es) | 2013-03-06 |
Family
ID=45044707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103973A AR083575A1 (es) | 2010-11-08 | 2011-10-27 | Aminopirazoles para inhibir la proteinquinasa chk1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9067920B2 (es) |
| EP (1) | EP2638033B1 (es) |
| JP (1) | JP5792316B2 (es) |
| KR (1) | KR101533166B1 (es) |
| CN (1) | CN103180311B (es) |
| AR (1) | AR083575A1 (es) |
| AU (1) | AU2011326230B2 (es) |
| BR (1) | BR112013010009B1 (es) |
| CA (1) | CA2816944C (es) |
| DK (1) | DK2638033T3 (es) |
| EA (1) | EA022096B1 (es) |
| ES (1) | ES2541414T3 (es) |
| HR (1) | HRP20150530T1 (es) |
| JO (1) | JO3145B1 (es) |
| ME (1) | ME02119B (es) |
| MX (1) | MX2013005181A (es) |
| PL (1) | PL2638033T3 (es) |
| PT (1) | PT2638033E (es) |
| RS (1) | RS54012B1 (es) |
| SI (1) | SI2638033T1 (es) |
| TW (1) | TWI501956B (es) |
| WO (1) | WO2012064548A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN108601781B (zh) | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| MX2023006364A (es) | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| JPWO2023120696A1 (es) | 2021-12-24 | 2023-06-29 | ||
| WO2023229032A1 (ja) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0412820A (pt) * | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
| EP1732920B1 (en) * | 2004-01-05 | 2011-03-09 | AstraZeneca AB | Thiophene derivatives as chk 1 inhibitors |
| JP2008501698A (ja) | 2004-06-04 | 2008-01-24 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 代謝の調節因子としての置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する疾患の予防および処置 |
| EP1888561A1 (en) * | 2005-05-05 | 2008-02-20 | AstraZeneca AB | Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
-
2011
- 2011-10-27 AR ARP110103973A patent/AR083575A1/es active IP Right Grant
- 2011-10-27 JO JOP/2011/0323A patent/JO3145B1/ar active
- 2011-10-28 TW TW100139492A patent/TWI501956B/zh active
- 2011-11-01 KR KR1020137011808A patent/KR101533166B1/ko active IP Right Grant
- 2011-11-01 US US13/877,923 patent/US9067920B2/en active Active
- 2011-11-01 PL PL11788263T patent/PL2638033T3/pl unknown
- 2011-11-01 ME MEP-2015-69A patent/ME02119B/me unknown
- 2011-11-01 BR BR112013010009-5A patent/BR112013010009B1/pt active IP Right Grant
- 2011-11-01 PT PT117882639T patent/PT2638033E/pt unknown
- 2011-11-01 EP EP11788263.9A patent/EP2638033B1/en active Active
- 2011-11-01 CN CN201180053779.8A patent/CN103180311B/zh active Active
- 2011-11-01 JP JP2013537756A patent/JP5792316B2/ja active Active
- 2011-11-01 MX MX2013005181A patent/MX2013005181A/es active IP Right Grant
- 2011-11-01 AU AU2011326230A patent/AU2011326230B2/en active Active
- 2011-11-01 CA CA2816944A patent/CA2816944C/en active Active
- 2011-11-01 EA EA201390499A patent/EA022096B1/ru not_active IP Right Cessation
- 2011-11-01 WO PCT/US2011/058692 patent/WO2012064548A1/en active Application Filing
- 2011-11-01 RS RS20150352A patent/RS54012B1/en unknown
- 2011-11-01 SI SI201130467T patent/SI2638033T1/sl unknown
- 2011-11-01 DK DK11788263T patent/DK2638033T3/en active
- 2011-11-01 ES ES11788263.9T patent/ES2541414T3/es active Active
-
2015
- 2015-05-18 HR HRP20150530TT patent/HRP20150530T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013010009A2 (pt) | 2020-09-29 |
| JP2013541586A (ja) | 2013-11-14 |
| US20130190262A1 (en) | 2013-07-25 |
| ME02119B (me) | 2015-10-20 |
| EP2638033A1 (en) | 2013-09-18 |
| DK2638033T3 (en) | 2015-04-27 |
| KR20130099146A (ko) | 2013-09-05 |
| EA201390499A1 (ru) | 2013-08-30 |
| CN103180311B (zh) | 2014-08-20 |
| US9067920B2 (en) | 2015-06-30 |
| CN103180311A (zh) | 2013-06-26 |
| PT2638033E (pt) | 2015-06-01 |
| CA2816944C (en) | 2015-12-22 |
| AU2011326230A1 (en) | 2013-05-09 |
| BR112013010009B1 (pt) | 2021-10-19 |
| JP5792316B2 (ja) | 2015-10-07 |
| JO3145B1 (ar) | 2017-09-20 |
| MX2013005181A (es) | 2013-10-17 |
| EP2638033B1 (en) | 2015-04-08 |
| HRP20150530T1 (hr) | 2015-06-19 |
| ES2541414T3 (es) | 2015-07-20 |
| SI2638033T1 (sl) | 2015-05-29 |
| EA022096B1 (ru) | 2015-10-30 |
| WO2012064548A1 (en) | 2012-05-18 |
| CA2816944A1 (en) | 2012-05-18 |
| AU2011326230B2 (en) | 2015-02-19 |
| KR101533166B1 (ko) | 2015-07-01 |
| TW201305138A (zh) | 2013-02-01 |
| RS54012B1 (en) | 2015-10-30 |
| PL2638033T3 (pl) | 2015-09-30 |
| TWI501956B (zh) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083575A1 (es) | Aminopirazoles para inhibir la proteinquinasa chk1 | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| PE20151412A1 (es) | Derivados de pirimidin-2,4-diamina para el tratamiento de cancer | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| PE20141038A1 (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201490759A1 (ru) | Ингибиторы протеинкиназы | |
| CO6680645A2 (es) | Inhibidores de oxadiazol de la producción de leucotrieno | |
| EA201690020A1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
| ES2691742T3 (es) | Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa | |
| ECSP13012964A (es) | Tratamientos combinados para neoplasias hematologicas malignas | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| BR112014002202A2 (pt) | macrociclos como inibidores de fator xia | |
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| NZ621386A (en) | Cyclopolysaccharide compositions | |
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| PE20121523A1 (es) | Metodo de tratamiento | |
| CO6361991A2 (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |